Edition:
United States

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

4,323JPY
2:00am EDT
Change (% chg)

¥-64 (-1.46%)
Prev Close
¥4,387
Open
¥4,386
Day's High
¥4,393
Day's Low
¥4,309
Volume
956,100
Avg. Vol
1,970,220
52-wk High
¥4,820
52-wk Low
¥2,284

Select another date:

Mon, May 14 2018

BRIEF-Zymeworks And Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused On Bispecific Antibodies

* ZYMEWORKS AND DAIICHI SANKYO EXPAND IMMUNO-ONCOLOGY COLLABORATION FOCUSED ON BISPECIFIC ANTIBODIES

BRIEF-Daiichi Sankyo to reorganize Kitasato Daiichi Sankyo Vaccine into specialized manufacturing unit

* Says it plans to reorganize unit Kitasato Daiichi Sankyo Vaccine Co., Ltd. into a unit specializing in manufacturing, effective April 1, 2019

BRIEF-‍Daiichi Sankyo And Darwinhealth Enter Exclusive Research Collaboration For Novel Cancer Target Initiative​

* ‍DAIICHI SANKYO AND DARWINHEALTH ENTER EXCLUSIVE RESEARCH COLLABORATION FOR NOVEL CANCER TARGET INITIATIVE​

BRIEF-Daiichi Sankyo completes share repurchase

* Says it accumulatively repurchased 15.7 million shares for 50 billion yen in total as of March 22

BRIEF-Fortis Healthcare Gets Court Order Relating To Daiichi Sankyo Co Case

* GETS COURT ORDER RELATING TO DAIICHI SANKYO COMPANY LIMITED CASE

BRIEF-Daiichi Sankyo Initiates Phase 2 Study Of DS-8201

* DAIICHI SANKYO INITIATES PHASE 2 STUDY OF DS-8201 IN PATIENTS WITH HER2-EXPRESSING ADVANCED COLORECTAL CANCER Source text for Eikon: Further company coverage:

BRIEF-Medrx signs joint development contract with DAIICHI SANKYO

* Says it signed a joint development contract with DAIICHI SANKYO COMPANY, LIMITED, regarding development candidates using Nano-sized Colloid Transdermal System owned by the company

BRIEF-Daiichi Sankyo's Regulatory Submission Triggers $20 Mln Milestone Payment To Exelixis​

* CO ‍ANNOUNCES COLLABORATOR DAIICHI SANKYO'S SUBMISSION OF REGULATORY FILING FOR ESAXERENONE (CS-3150) IN JAPAN​

BRIEF-Daiichi Sankyo Initiates Phase 1 Study Of DS-1062 In Patients With Advanced Non-Small Cell Lung Cancer

* DAIICHI SANKYO INITIATES PHASE 1 STUDY OF DS-1062 IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER Source text for Eikon: Further company coverage:

Select another date: